Assignee
ALKAHEST INC
US·24 granted patents·21 pending applications·79 citations·filing 2013–2024
Top patents by PatentIndex Score
45 records- 0194US10357513B2Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma productsALKAHEST INC·Filed 2018·Granted Jul 23, 2019·17 cites·10 claims
- 0292US11298377B2Methods of improving wound healingALKAHEST INC·Filed 2019·Granted Apr 12, 2022·4 cites·18 claims
- 0392US11103530B2Methods of improving or accelerating postoperative recoveryALKAHEST INC·Filed 2019·Granted Aug 31, 2021·7 cites·5 claims
- 0492US10525107B2Blood plasma fractions as a treatment for aging-associated cognitive disordersALKAHEST INC·Filed 2017·Granted Jan 7, 2020·12 cites·8 claims
- 0591US11484551B2Method of treating liver failure with plasma fraction IV-4ALKAHEST INC·Filed 2021·Granted Nov 1, 2022·2 cites·15 claims
- 0691US11439687B2Blood plasma fractions for use in muscle regenerationALKAHEST INC·Filed 2020·Granted Sep 13, 2022·3 cites·8 claims
- 0789US11951102B2Methods and compositions for treating retina-associated disease using CCR3-inhibitorsALKAHEST INC·Filed 2023·Granted Apr 9, 2024·1 cites·26 claims
- 0889US10245285B2Blood plasma and plasma fractions as therapy for tumor growth and progressionALKAHEST INC·Filed 2017·Granted Apr 2, 2019·11 cites·18 claims
- 0987US10874692B2Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma productsALKAHEST INC·Filed 2019·Granted Dec 29, 2020·6 cites·13 claims
- 1085US10905717B2Blood plasma and plasma fractions as therapy for tumor growth and progressionALKAHEST INC·Filed 2019·Granted Feb 2, 2021·5 cites·13 claims
- 1184US11957671B2Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseasesALKAHEST INC·Filed 2022·Granted Apr 16, 2024·1 cites·13 claims
- 1284US11547724B2Methods of treating a subject for painALKAHEST INC·Filed 2020·Granted Jan 10, 2023·1 cites·8 claims
- 1384US11413308B2Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma productsALKAHEST INC·Filed 2020·Granted Aug 16, 2022·1 cites·19 claims
- 1481US11426399B2Treatment of aging-associated disease with modulators of leukotriene A4 hydrolaseALKAHEST INC·Filed 2019·Granted Aug 30, 2022·1 cites·17 claims
- 1579US2023285455A1Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative RecoveryALKAHEST INC·Filed 2023·Application pending·0 cites
- 1678US12053489B2Blood plasma fractions for use in liver regenerationALKAHEST INC·Filed 2022·Granted Aug 6, 2024·0 cites·12 claims
- 1778US11590118B2Methods and compositions for treating retina-associated disease using CCR3-inhibitorsALKAHEST INC·Filed 2018·Granted Feb 28, 2023·1 cites·37 claims
- 1877US2024342212A1Blood Plasma Fractions for Use in Liver RegenerationALKAHEST INC·Filed 2024·Application pending·0 cites
- 1977US2023111752A1Use of Plasma and Plasma Fractions for Improvement of Pain, Wound Healing, and Postoperative RecoveryALKAHEST INC·Filed 2022·Application pending·0 cites
- 2074US12059453B2Blood plasma fractions for use in muscle regenerationALKAHEST INC·Filed 2022·Granted Aug 13, 2024·0 cites·9 claims
- 2174US2024358802A1Blood Plasma Fractions for Use in Muscle RegenerationALKAHEST INC·Filed 2024·Application pending·0 cites
- 2273US11040068B2Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma productsALKAHEST INC·Filed 2019·Granted Jun 22, 2021·1 cites·14 claims
- 2373US10213421B2Pharmaceutical formulations comprising CCR3 antagonistsALKAHEST INC·Filed 2013·Granted Feb 26, 2019·5 cites·17 claims
- 2470US2023346764A1Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-InhibitorsALKAHEST INC·Filed 2023·Application pending·0 cites
- 2569US2020375971A1Use of CCR3-InhibitorsALKAHEST INC·Filed 2020·Application pending·0 cites
- 2669US2022226304A1Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 HydrolaseALKAHEST INC·Filed 2022·Application pending·0 cites
- 2767US11344542B2Treatment of aging-associated disease with modulators of leukotriene A4 hydrolaseALKAHEST INC·Filed 2020·Granted May 31, 2022·0 cites·3 claims
- 2866US12496296B2Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseasesALKAHEST INC·Filed 2024·Granted Dec 16, 2025·0 cites·20 claims
- 2966US2024076369A1Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 ModulatorsALKAHEST INC·Filed 2022·Application pending·0 cites
- 3064US2022152161A1Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive DisordersALKAHEST INC·Filed 2022·Application pending·0 cites
- 3163US2021113612A1Blood Plasma and Plasma Fractions as Therapy for Tumor Growth and ProgressionALKAHEST INC·Filed 2020·Application pending·0 cites
- 3261US11660316B2Methods of inducing liver regeneration by administering a plasma protein fractionALKAHEST INC·Filed 2020·Granted May 30, 2023·0 cites·8 claims
- 3361US2021301013A1Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 ModulatorsALKAHEST INC·Filed 2021·Application pending·0 cites
- 3460US2023069856A1Blood Plasma Fractions for Improvement of MyelinationALKAHEST INC·Filed 2022·Application pending·0 cites
- 3560US2021315932A1Dosing Regimen for Treatment of Cognitive and Motor Impairments with Blood Plasma and Blood Plasma ProductsALKAHEST INC·Filed 2021·Application pending·0 cites
- 3659US2019111042A1Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-InhibitorsALKAHEST INC·Filed 2018·Application pending·0 cites
- 3759US2017319567A1Use of CCR3-InhibitorsALKAHEST INC·Filed 2017·Application pending·0 cites
- 3858US11612596B2Pharmaceutical formulations comprising CCR3 antagonistsALKAHEST INC·Filed 2020·Granted Mar 28, 2023·0 cites·16 claims
- 3957US2023399380A1Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant ProteinsALKAHEST INC·Filed 2023·Application pending·0 cites
- 4052US2021171626A1Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 ModulatorsALKAHEST INC·Filed 2020·Application pending·0 cites
- 4150US2019321449A1Blood Plasma Fractions as a Treatment for Aging-Associated Cognitive DisordersALKAHEST INC·Filed 2019·Application pending·0 cites
- 4250US2020054622A1Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-InhibitorsALKAHEST INC·Filed 2019·Application pending·0 cites
- 4348US11382907B2Methods and compositions for treating aging-associated impairments using CCR3-inhibitorsALKAHEST INC·Filed 2018·Granted Jul 12, 2022·0 cites·16 claims
- 4447US2019151300A1Pharmaceutical Formulations Comprising CCR3 AntagonistsALKAHEST INC·Filed 2018·Application pending·0 cites
- 4540US2023312697A1Methods of improving retina-associated disease outcome using ccr3-inhibitorsALKAHEST INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ALKAHEST INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →